Etelcalcetide is a synthetic peptide that functions as a calcimimetic agent, primarily used in the management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis. Its mechanism of action involves the modulation of calcium-sensing receptors, leading to a decrease in parathyroid hormone (PTH) secretion. This helps to regulate calcium and phosphate metabolism, thereby reducing the risk of bone disease associated with elevated PTH levels. Etelcalcetide is administered via intravenous injection and has a longer half-life compared to other calcimimetics, allowing for less frequent dosing. The substance is characterized by its specific amino acid sequence, which contributes to its biological activity, and it is typically formulated as a sterile solution for injection. As with any medication, potential side effects may include nausea, vomiting, and hypocalcemia, necessitating careful monitoring of calcium levels during treatment. Overall, etelcalcetide represents an important therapeutic option for managing mineral and bone disorders in patients with renal impairment.

Etelcalcetide

1262780-97-1: Etelcalcetide is a synthetic peptide that functions as a calcimimetic agent, primarily used in the management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis. Its mechanism of action involves the modulation of calcium-sensing receptors, leading to a decrease in parathyroid hormone (PTH) secretion. This helps to regulate calcium and phosphate metabolism, thereby reducing the risk of bone disease associated with elevated PTH levels. Etelcalcetide is administered via intravenous injection and has a longer half-life compared to other calcimimetics, allowing for less frequent dosing. The substance is characterized by its specific amino acid sequence, which contributes to its biological activity, and it is typically formulated as a sterile solution for injection. As with any medication, potential side effects may include nausea, vomiting, and hypocalcemia, necessitating careful monitoring of calcium levels during treatment. Overall, etelcalcetide represents an important therapeutic option for managing mineral and bone disorders in patients with renal impairment.

Etelcalcetide Pentatrifluoroacetate

<p>Etelcalcetide (AMG 416), a synthetic peptide CaSR activator, treats secondary hyperparathyroidism in hemodialysis patients.</p>

<p>Agonist of calcium sensing receptor CASR; calcimimetic agent</p>

CAS 1262780-97-1

Etelcalcetide

Etelcalcetide Pentatrifluoroacetate

Ref: 4Z-PE-192002

Etelcalcetide

Ref: TM-TP1235

Etelcalcetide

Ref: 4Z-PE-192001

Etelcalcetide

Ref: 3D-FE162097